Cupid shares jumped 6% on Friday, extending their sharp 13% rally over two days as the multibagger stock continued to deliver exceptional returns for its more than 2 lakh shareholders. The stock rose to ₹222 apiece on Friday, building on its earlier recovery that saw shares climb 11% to ₹216 on Thursday after tumbling nearly 12% in the previous session. The recovery reflected renewed investor confidence, supported by the company's strong business momentum and upgraded growth outlook. Cupid shares have gained around 110% so far in 2026 and surged about 900% over the past year, placing it among notable multibagger performers in the market. Over the longer term, the stock has delivered returns of more than 8,600% in three years and around 8,800% in five years.
The company has raised its FY27 revenue guidance by at least 10%, now targeting revenue of ₹660 crore+ compared with its earlier guidance of ₹600 crore. As reported by The Economic Times, the company is on track to deliver quarterly revenue exceeding ₹150 crore in Q1 FY27, marking one of the strongest quarterly performances in its history. The revised outlook reflects increasing confidence in Cupid's diversified business model, expanding global opportunity pipeline, and growing scale across healthcare, personal care, and wellness segments. Commenting on the company's performance, Aditya Kumar Halwasiya, Chairman and Managing Director of Cupid Limited, said the strong start to FY27 reflects the transformation the company achieved over the past few years. The company also continues to make steady progress in its In Vitro Diagnostics (IVD) business, with management believing the segment has potential to become a meaningful contributor over the coming years, supported by regulatory approvals, new product launches, and continued commercialisation efforts.
Technical experts identify the ₹177–185 zone as immediate support, aligning closely with the 20-Day EMA and recent breakout region. A stronger support is placed near ₹155–160, coinciding with the 50-Day EMA. As long as the stock sustains above these crucial support levels, the overall trend is likely to remain positive, with the potential to retest ₹225–230 in the near term. However, a decisive breach below the ₹177–185 support zone could trigger further profit booking and lead to a short-term retracement towards the ₹155–160 support region. Virat Jagad, Technical Research Analyst at Bonanza, notes that the rally reflects strong bullish momentum supported by sustained buying interest and higher trading volumes, with the stock continuing to trade comfortably above key short-and long-term moving averages.
According to the company's filing, growth is expected to be supported by strong momentum in its international B2B business, supported by increasing opportunities in private markets, institutional procurement, and government tenders globally. The outlook is further supported by the commencement of its long-term supply agreement with the Partnership for Supply Chain Management (PFSCM), Netherlands, which started on an encouraging note, strengthening its position in global healthcare procurement. The company also sees significant growth potential in its lubricant portfolio amid rising adoption across institutional and consumer segments, and expects its consumer business to benefit from continued expansion of personal care and wellness products across modern trade, organised retail and pharmacy networks across India. Cupid operates a manufacturing facility in Sinnar near Nashik, about 200 km from Mumbai, and says it is the first company in the world to receive prequalification from the World Health Organisation and United Nations Population Fund for the supply of both male and female condoms.
Over the past year, Cupid expanded its Male Condom and Female Condom businesses through enhanced manufacturing capabilities, customer acquisition initiatives, and wider market reach. As reported by The Economic Times, the lubricants portfolio also continued to gain traction across institutional and consumer segments. The company remains focused on building Cupid into a trusted mainstream personal care and wellness brand, with expansion plans across modern trade, organised retail, and pharmacy channels. Management emphasized that on the consumer side, they see significant long-term opportunities across modern trade, organised retail, and pharmacy channels as they continue to expand their presence across Bharat. The company enters the rest of FY27 with one of the strongest order books and opportunity pipelines in its history, according to management, with rising global demand, diversified business verticals, expanding manufacturing capabilities, and continued investments supporting a new phase of sustainable growth.
